6 minute read
Nov. 14, 2023

Zunsemetinib: A p38α-MK2 Complex Inhibitor Intended for Inflammation


oral p38a-MK2 inhibitor Ph. IIa for hidradenitis suppurativa (failed) rational design from ATP-competitive molecule Press release, March 6, 2023 Confluence, MO / Aclaris Therapeutics, PA

Drug Hunter Team

Zunsemetinib (ATI-450, CDD-450) is a p38α- MK2 complex inhibitor discovered by Confluence Technologies and developed by Confluence spinout, Aclaris Therapeutics. The molecule has a unique molecular glue-like mechanism of action that held promise in immunology, but sadly recent results have led to its discontinuation. This article reviews the target, its mechanism, and why it mattered.



Other molecules you may be interested in